What the business is, and whether it's a good one at a fair price.
Manufactures and sells active pharmaceutical ingredients (APIs) to other pharmaceutical companies globally, with FY26 revenue of ₹2,551.832 crore. The business is split between a non-GPL portfolio (branded/innovator customer products) that contributed 71% of revenue and grew 13% in FY26, a smaller GPL (generic) business that de-grew 4.9% in FY26, and a CDMO (contract development and manufacturing) segment that grew 18% in FY26 and contributes around 7% of sales. A pipeline of 28-29 high-potency API molecules is being built against an addressable market of $82 billion, with commercial revenue flagged from FY28 onward. Current manufacturing capacity of 1,198 KL (FY24) is planned to expand to 2,690 KL by FY28, anchored by a new Solapur facility (370 KL for backward integration plus 120 KL for API block) targeted for Q2 FY27 commissioning; FY27 capex is set at ~₹540 crore. The portfolio spans 176 unique molecules with 11 new launches in FY26, ~900 customers globally, and 617 DMF/CEP filings. Therapeutic mix is concentrated in cardiovascular and CNS therapies (58% of topline), with chronic therapies at 70% of sales. R&D spend ran at 3.7% of sales in Q1 FY27, with a ~4% medium-term target. The largest cost is raw materials at 41.7% of revenue, followed by employee costs at 10.7%.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ALIVUS LIFE SCIENCES LTD's filed financials and exchange disclosures
ALIVUS LIFE SCIENCES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ALIVUS.
Yes. Over the trailing twelve months ALIVUS LIFE SCIENCES LTD reported a net profit of ₹603 Cr on revenue of ₹2,590 Cr.
Yes. The dividend yield is 0.36% at the current price. It paid out 11% of its profit as dividend in FY26.
Effectively yes. It holds ₹2 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, ALIVUS LIFE SCIENCES LTD ranks 82 of 169 in Pharmaceuticals — cheaper than 52% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ALIVUS LIFE SCIENCES LTD moves 0.91% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ALIVUS LIFE SCIENCES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
